While the advantages of fecal DNA-based molecular screening are generally accepted, the
technical hurdle is substantial. Problems include identification of molecular markers that are
reliably informative, degradation of DNA associated with remote collection and shipping of
samples, and reliable isolation of sufficient DNA from a challenging matrix. Each problem
offers the opportunity for IP generation, and indeed GLC has the necessary broad patent
portfolio and know-how required to fully implement a screen. GLC's essential IP includes an
exclusive panel (patented) of DNA markers and a patented sample preservation buffer as well
as considerable know-how and trade secrets enabling a robust, cost effective process spanning
the entire procedure, from stool collection through DNA analysis.

HOMEABOUT USPRODUCTSNEWSCONTACT US
GLC BIOTECHNOLOGY, INC.
A molecular cancer dignostics company
Team
GLC's Advantages
GLC's Intellectual Property